此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

索马鲁肽用于戒烟后体重管理

2026年9月16日 更新者:Luba Yammine、The University of Texas Health Science Center, Houston

每周一次索马鲁肽限制超重/肥胖成年吸烟者戒烟后体重增加的随机对照试验

This trial will examine the effect of semaglutide 2.4mg on changes in body weight, body composition, and peripheral and central mechanisms that control appetite, satiety, and food intake in the context of smoking cessation.

研究概览

研究类型

介入性

注册 (估计的)

197

阶段

  • 阶段2

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

研究联系人备份

学习地点

    • Texas
      • Austin、Texas、美国、78723
      • Houston、Texas、美国、77054
        • 招聘中
        • The University of Texas Health Science Center at Houston
        • 接触:
        • 接触:
        • 首席研究员:
          • Luba Yammine, PhD

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 至 75年 (成人、年长者)

接受健康志愿者

是的

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Ability to provide informed consent before any study-related activity, willing to comply with al study procedures, and be available for the duration of the study.
  • Body mass index (BMI) ≥30 kg/m2 or ≥27 kg/m2 with the presence of at least one of the following weight-related comorbidities (treated or untreated): hypertension (unless meets medical exclusion criterion 7), cardiovascular disease (unless meets medical exclusion criterion 6), dyslipidemia, or obstructive sleep apnea
  • Have been smoking ≥5 cigarettes per day for at least 1 year (prior to screening) and provide positive cotinine test.
  • Desire to quit smoking (defined as "intend to quit within one month")
  • Agree (if the participant is female and of child-bearing potential) to use effective contraceptive methods, unless the participant's male partner(s) is surgically sterile (underwent vasectomy).
  • Women of child-bearing potential must provide negative urine pregnancy tests prior to randomization.
  • Normal cognitive restraint (assessed as cognitive restraint score of <4 from the Three Factor Eating Habits Questionnaire)
  • Have a medical history and a brief physical examination demonstrating no clinically significant contraindications for study participation, in the judgment of the Study Physician and the Principal Investigator

Exclusion Criteria:

Medical Exclusions

  • Personal or first-degree relative(s) history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN 2).
  • Acute pancreatitis within the past 6 months prior to screening.
  • History or presence of chronic pancreatitis.
  • Type 1 or type 2 Diabetes Mellitus (previously diagnosed or indicated by HbA1C ≥48 mmol/mol (6.5%) as measured by central laboratory at screening).
  • End stage renal disease (ESRD, previously diagnosed or indicated by estimated glomerular filtration rate (eGFR) value of eGFR < 15 ml/min/1.73 m2 as measured by central laboratory at screening).
  • Any of the following: myocardial infarction, stroke, hospitalization for unstable angina or transient ischemic attack within the past 60 days prior to screening.
  • Systolic blood pressure (SBP) >159 mmHg and/or diastolic blood pressure (DBP) >99 mmHg)
  • History of malignant neoplasms within the past 5 years prior to screening. Basal and squamous cell skin cancer and any carcinoma in-situ are allowed.
  • Severe gastrointestinal disease (i.e., severe gastroparesis).
  • Known or suspected hypersensitivity to nicotine/nicotine patches; semaglutide, excipients, or related products.
  • Women who are currently pregnant, or plan to become pregnant, or lactating, or of childbearing potential and are not using medically accepted forms of contraception.
  • Have any illness or condition which in the opinion of the Principal Investigator and/or the Study Physician would preclude safe and/or successful completion of the study.

Psychiatric / Substance Use Exclusions

  • Psychoactive substance abuse or dependence (excluding nicotine dependence) within the past 3 months prior to screening (existing diagnosis or as determined by the structured interview).

  • Urine drug test positive, before randomization, for any of the following substances:

    1. benzodiazepines
    2. cocaine
    3. opioids
    4. amphetamines
    5. methamphetamine
    6. buprenorphine
    7. barbiturates
    8. 3,4-methylenedioxy-methamphetamine (MDMA)
    9. Tetrahydrocannabinol (THC)
  • Psychotic or bipolar disorder, or mood disorder with psychotic features; or eating disorder (existing clinical diagnosis or as determined by the structured interview)

  • Moderate to high risk for suicidality (as determined by the structured interview).

Weight-Related Exclusions

  • Previously undergone bariatric surgery
  • Gained/lost ≥4.5 kg over the past 6 months (prior to screening)
  • Currently enrolled in a behavioral weight management plan
  • Uncontrolled thyroid disease (the criterion will be assessed at the Study Physician's and the Principal Investigator's discretion)

Smoking-Related Exclusions

-Currently using other combustible (e.g., cigars), other (e.g., chewing tobacco, snuff, snus) or alternative (e.g., electronic cigarettes) tobacco products

Medication-Related Exclusions

  • Currently using oral or injectable glucose lowering medications
  • Currently using pharmacotherapy for smoking cessation (NRT, varenicline, or bupropion)
  • Currently or recently (last 90 days prior to screening) taking medication used for weight management (i.e., orlistat, lorcaserin,vi naltrexone-bupropion, liraglutide, phentermine, topiramate, benzphetamine, diethylpropion, phendimetrazine)
  • Currently or recently (within the past 14 days prior to screening) taking medication(s) known to impact appetite and/or weight (i.e., corticosteroids, excluding inhaled)

General Exclusions

  • Current, anticipated, or pending enrollment in another research study during this trial that could potentially affect participant safety and/or the study data/design as determined by the Principal Investigator and/or Study Physician.
  • Not planning to live in the area for the duration of this trial.
  • Surgery scheduled for the duration of the trial, except for minor surgical procedures, in opinion of the Principal Investigator and/or the Study Physician.
  • Unable to communicate (read, write, and speak) fluently in English.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:四人间

武器和干预

参与者组/臂
干预/治疗
安慰剂比较:安慰剂

Participants who smoke >10 cigarettes/day will use 21 mg patches for the first 6 weeks, 14 mg patches during weeks 7 and 8, and 7 mg patches during weeks 9 and 10. Participants who smoke 5-10 cigarettes per day will use 14 mg patches for the first 6 weeks and 7 mg patches for weeks 7-10.

Participants will receive weekly, manual-based individual smoking cessation counseling. Counseling will be provided by master's level clinicians.

Non-active medication, self-administered

实验性的:索马鲁肽

Semaglutide 2.4mg will be self-administered once a week under the surface of the skin and will be started at 0.24mg or 0.25mg once a week for 4 weeks; in 4-week intervals, the dose will be increased until a dose of 2.4mg is reached

Participants who smoke >10 cigarettes/day will use 21 mg patches for the first 6 weeks, 14 mg patches during weeks 7 and 8, and 7 mg patches during weeks 9 and 10. Participants who smoke 5-10 cigarettes per day will use 14 mg patches for the first 6 weeks and 7 mg patches for weeks 7-10.

Participants will receive weekly, manual-based individual smoking cessation counseling. Counseling will be provided by master's level clinicians.

研究衡量的是什么?

主要结果指标

结果测量
大体时间
体重百分比变化
大体时间:第 28 周的基线
第 28 周的基线

次要结果测量

结果测量
大体时间
体重变化(以千克 (kg) 为单位)
大体时间:第 28 周的基线
第 28 周的基线
以千克 (kg) 为单位测量的身体脂肪量变化
大体时间:第 28 周的基线
第 28 周的基线
腰围变化(以厘米为单位)
大体时间:第 28 周的基线
第 28 周的基线

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Luba Yammine, PhD、The University of Texas Health Science Center, Houston

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2024年4月23日

初级完成 (估计的)

2028年5月25日

研究完成 (估计的)

2028年6月25日

研究注册日期

首次提交

2023年12月7日

首先提交符合 QC 标准的

2023年12月7日

首次发布 (实际的)

2023年12月18日

研究记录更新

最后更新发布 (实际的)

2026年9月21日

上次提交的符合 QC 标准的更新

2026年9月16日

最后验证

2026年9月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

在美国制造并从美国出口的产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅